Convergent Therapeutics Appoints Barbara Duncan to Board of Directors
News & media
Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial
Convergent Therapeutics Announces First Patient Treated in Phase II Clinical Trial with Lead Therapeutic Candidate and Corporate Updates
Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023